Sort
10,766 grants matching “checkpoint inhibitor”
Combining targeted radionuclide therapy with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses
$327,645Paul M Sondel · University Of Wisconsin-Madison · P01 · FY2021 · CA
E2A/HEB TRANSCRIPTION FACTORS IN T CELL DEVELOPMENT
$327,600Yuan Zhuang · Duke University · R01 · FY2009 · GM
E2A/HEB TRANSCRIPTION FACTORS IN T CELL DEVELOPMENT
$327,600Yuan Zhuang · Duke University · R01 · FY2008 · GM
Regulation of DNA replication kinetics by BRCA2 after DNA damage
$327,533Bing Xia · Rutgers Biomedical And Health Sciences · R01 · FY2024 · CA
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
$327,396Brent Allen Hanks · Duke University · R37 · FY2023 · CA
The Role of AKT in Prostate Cancer
$327,393William R Sellers · Beth Israel Deaconess Medical Center · P01 · FY2009 · CA
Immunomodulatory effects of bortezomib on antitumor CD8 T-NK cell crosstalk
$327,375Anil Shanker · Meharry Medical College · SC1 · FY2020 · CA
Immunomodulatory effects of bortezomib on antitumor CD8 T-NK cell crosstalk
$327,375Anil Shanker · Meharry Medical College · SC1 · FY2019 · CA
Immunomodulatory effects of bortezomib on antitumor CD8 T-NK cell crosstalk
$327,375Anil Shanker · Meharry Medical College · SC1 · FY2018 · CA
Immunomodulatory effects of bortezomib on antitumor CD8 T-NK cell crosstalk
$327,375Anil Shanker · Meharry Medical College · SC1 · FY2017 · CA
A Phospholipid-Derived Nanotherapeutic Platform for Improved Colorectal Cancer Immunochemotherapy
$327,374Jianqin Lu · University Of Arizona · R01 · FY2024 · CA
Integration of stromal targeting agents with immune checkpoint therapy
$327,273Lei Zheng · Johns Hopkins University · P01 · FY2024 · CA
Oncolytic Adenoviruses for Glioma Therapy
$327,149Frederick F Lang · University Of Tx Md Anderson Can Ctr · P50 · FY2020 · CA
Role of T Regulatory Cell Suppression in Autoimmunity and Cancer
$326,956Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Expression of Class I Specific Receptors in NK Cells
$326,926David H Raulet · University Of California Berkeley · R01 · FY2007 · AI
A novel approach for the selective inhibition of HIF-2a in kidney cancer
$326,834Mei Yee Koh · University Of Utah · R01 · FY2019 · CA
Function and mechanism of REDD1 signaling to TSC1/2 and mTORC1
$326,800Leif W Ellisen · Massachusetts General Hospital · R01 · FY2009 · CA
Manipulation of Tumor Specific Immunity
$326,781Hans Schreiber · University Of Chicago · R01 · FY2022 · CA
Mechanism of ultraviolet radiation induced immune tolerance
$326,700Hui Xu · University Of Alabama At Birmingham · R01 · FY2018 · AR
Mechanism of ultraviolet radiation induced immune tolerance
$326,700Hui Xu · University Of Alabama At Birmingham · R01 · FY2020 · AR
Mechanism of ultraviolet radiation induced immune tolerance
$326,700Hui Xu · University Of Alabama At Birmingham · R01 · FY2019 · AR
Combining targeted radionuclide therapy with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses
$326,693Paul M Sondel · University Of Wisconsin-Madison · P01 · FY2020 · CA
Project 3: Modulating Androgen Receptor Signaling to Enhance the Efficacy of CAR T Cell Therapy for Advanced Prostate Cancer
$326,549John Kyung Lee · Fred Hutchinson Cancer Center · P50 · FY2023 · CA
The replication checkpoint and genomic fidelity in skin
$326,427Paul Nghiem · University Of Washington · R01 · FY2006 · AR
Targeting the MET Pathway in Urothelial Carcinoma
$326,245Andrea Apolo · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA